Ischemia
-
Hemostemix Plans to Revolutionize Stem Cell Therapy with Scalable Production and New Sales Goals
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for…
-
Thomas Smeenk of Hemostemix talks about market reaction to successful litigation settlement
In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and…
-
Hemostemix’s stem cell therapy pursues ‘Your Fountain of Youth’
What’s a company worth to investors that could improve numerous medical conditions related to ischemia (lack of blood…
-
Revolutionizing the way we treat lack of blood flow diseases by using stem cell therapy
Every year modern medicine makes new breakthroughs that continue to amaze. Today’s company has a breakthrough ‘stem cell…
-
Thomas Smeenk on Hemostemix’s autologous stem cell therapy technology and why some call it ‘the fountain of youth’
In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
-
Fully funded with strong IP Portfolio, Hemostemix marches forward towards FDA Phase II Clinical Trial Completion
Hemostemix Inc. (TSXV: HEM | OTC: HMTXF) continues to move forward with its FDA Phase II clinical trial…
-
Hemostemix CEO on ACP’s Response to Ischemia in the Circulatory System
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
-
Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
